MTSTOTCinactive

METASTAT, INC.

Healthcare·Oncology·Commercial·Boston, MA, United States
Oncology

METASTAT, INC. (MTST): 4 pipeline candidates. Updated within the last hour.

9.1/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.47 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for METASTAT, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$6K

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (4 candidates)

DrugPhase
mapkapk2 inhibitorPreclinical
mena-targeted therapeutic candidatesPreclinical
menacalcApproved
metasite breastApproved

Frequently asked questions

How many drug candidates are in METASTAT, INC.'s pipeline?

METASTAT, INC. (MTST) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is METASTAT, INC.'s lead drug candidate?

METASTAT, INC.'s most advanced tracked candidate is mapkapk2 inhibitor (Preclinical) for MENA-positive solid tumors (including pancreatic, glioblastoma, bladder, colorectal and triple negative breast cancer).

What is METASTAT, INC.'s market capitalization?

METASTAT, INC.'s market capitalization is approximately $6K.

Get the full picture on METASTAT, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar